Trial Profile
Randomized phase II study of osimertinib plus bevacizumab and osimertinib for chemotherapy-naive patients with nonsquamous non-small cell lung cancer harboring EGFR mutations (investigator-initiated multicenter clinical trial, WJOG9717L)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Oct 2022
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary) ; Bevacizumab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms FLAIR
- 13 Oct 2022 According to UMIN record, Date analysis concluded 26 May 222
- 13 Oct 2022 Status changed from active, no longer recruiting to completed.
- 13 Sep 2022 Final results assessing Osimertinib plus bevacizumab with Osimertinib monotherapy for untreated pts with advanced EGFR mutated non squamous non-small cell lung cancer presented at the 47th European Society for Medical Oncology Congress